[go: up one dir, main page]

WO2008117730A1 - 肝疾患の予防または治療用組成物 - Google Patents

肝疾患の予防または治療用組成物 Download PDF

Info

Publication number
WO2008117730A1
WO2008117730A1 PCT/JP2008/055143 JP2008055143W WO2008117730A1 WO 2008117730 A1 WO2008117730 A1 WO 2008117730A1 JP 2008055143 W JP2008055143 W JP 2008055143W WO 2008117730 A1 WO2008117730 A1 WO 2008117730A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
lung disease
preventing
treating lung
asn
Prior art date
Application number
PCT/JP2008/055143
Other languages
English (en)
French (fr)
Inventor
Hiroo Sanada
Kenji Sato
Shin Ono
Yoshio Suzuki
Original Assignee
Nisshin Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nisshin Pharma Inc. filed Critical Nisshin Pharma Inc.
Priority to US12/532,765 priority Critical patent/US20100190723A1/en
Priority to CN2008800152149A priority patent/CN101687909B/zh
Priority to AU2008230460A priority patent/AU2008230460A1/en
Priority to JP2009506311A priority patent/JPWO2008117730A1/ja
Priority to CA002681593A priority patent/CA2681593A1/en
Priority to EP08722517A priority patent/EP2151451A4/en
Publication of WO2008117730A1 publication Critical patent/WO2008117730A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C07K5/0825—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Glp-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT OF FLOUR OR DOUGH FOR BAKING, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS
    • A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
    • A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
    • A21D2/24—Organic nitrogen compounds
    • A21D2/245—Amino acids, nucleic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L23/00—Soups; Sauces; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06173—Dipeptides with the first amino acid being heterocyclic and Glp-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

　効果が高く、副作用の心配がなく、摂取が容易であり、且つ価格的にも安全性の面からも長期間服用ができる肝疾患の予防および／または治療効果のある組成物を提供する。本発明は、次式：ｐｙｒｏＧｌｕ－（Ｘ）ｎ－Ａ（Ｘは同一または異なって、ＧｌｎまたはＡｓｎであり、ＡはＧｌｎ、Ａｓｎ、Ｌｅｕ、ＩｌｅまたはＶａｌであり、ｎは０～２の整数である）で表されるアミノ酸配列からなるペプチドまたはその塩に関する。
PCT/JP2008/055143 2007-03-23 2008-03-19 肝疾患の予防または治療用組成物 WO2008117730A1 (ja)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US12/532,765 US20100190723A1 (en) 2007-03-23 2008-03-19 Preventive or therapeutic composition for liver disease
CN2008800152149A CN101687909B (zh) 2007-03-23 2008-03-19 预防或治疗肝脏疾病的组合物
AU2008230460A AU2008230460A1 (en) 2007-03-23 2008-03-19 Preventive or therapeutic composition for liver disease
JP2009506311A JPWO2008117730A1 (ja) 2007-03-23 2008-03-19 肝疾患の予防または治療用組成物
CA002681593A CA2681593A1 (en) 2007-03-23 2008-03-19 Preventive or therapeutic composition for liver disease
EP08722517A EP2151451A4 (en) 2007-03-23 2008-03-19 COMPOSITION FOR PREVENTION BZW. TREATMENT OF LUNG DISEASES

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-077594 2007-03-23
JP2007077594 2007-03-23

Publications (1)

Publication Number Publication Date
WO2008117730A1 true WO2008117730A1 (ja) 2008-10-02

Family

ID=39788466

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/055143 WO2008117730A1 (ja) 2007-03-23 2008-03-19 肝疾患の予防または治療用組成物

Country Status (8)

Country Link
US (1) US20100190723A1 (ja)
EP (1) EP2151451A4 (ja)
JP (1) JPWO2008117730A1 (ja)
KR (1) KR101566036B1 (ja)
CN (1) CN101687909B (ja)
AU (1) AU2008230460A1 (ja)
CA (1) CA2681593A1 (ja)
WO (1) WO2008117730A1 (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012029616A (ja) * 2010-07-30 2012-02-16 Ogawa & Co Ltd 風味増強剤
JP2018518192A (ja) * 2015-05-04 2018-07-12 浙江海正薬業股▲ふん▼有限公司Ｚｈｅｊｉａｎｇ Ｈｉｓｕｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ ＣＯ．，ＬＴＤ． ブロッコリータンパク質のペプチドを調製する方法、それによって調製されたブロッコリータンパク質のペプチド、および、その使用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102224161B (zh) * 2008-09-22 2016-03-30 日清药业股份有限公司 抗炎症肽
CN104918502B (zh) * 2013-01-22 2017-05-31 马斯公司 风味组合物和包含风味组合物的可食用组合物
WO2014177989A2 (en) * 2013-04-29 2014-11-06 Chigurupati Technologies Private Limited Reduced toxicity in alcoholic beverages
KR101935762B1 (ko) 2018-08-25 2019-01-04 김민재 동물 투약 보조용 조성물 및 이의 제조방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5419966A (en) * 1977-07-13 1979-02-15 Showa Denko Kk Production of pyroglutamine peptide
WO2002072131A1 (fr) 2001-03-12 2002-09-19 Ajinomoto Co., Inc. Médicaments contre des affections hépatiques
JP2007077594A (ja) 2005-09-12 2007-03-29 Clion Co Ltd アンカー金具埋設軽量気泡コンクリートパネル及びその製造方法並びにその製造装置

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US77191A (en) * 1868-04-28 Chaeles
JPS59204698A (ja) * 1983-05-06 1984-11-20 カネボウ株式会社 透明石ケン
IT1172391B (it) * 1983-12-23 1987-06-18 Polifarma Spa Composti tirpeptidici contenenti acido piroglutaminico e triptofano,procedimentio di produzione ed applicazioni terapeutiche
IT1186733B (it) * 1985-06-05 1987-12-16 Eniricerche Spa Composti tripeptidici ad azione ipotensiva
US5308753A (en) * 1992-02-20 1994-05-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods for purifying and detecting IGM antibodies
IT1256178B (it) * 1992-11-30 1995-11-29 Lorenzo Ferrari Composti ad attivita' terapeutica utili per il trattamento di malattieconnesse ad una carenza di glutatione, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.
JPH09100297A (ja) * 1995-10-03 1997-04-15 Ajinomoto Co Inc 新規ピログルタミルペプチド
US6716963B1 (en) * 1998-05-22 2004-04-06 Abbott Laboratories Peptide antiangiogenic drugs
MXPA03000626A (es) * 2000-07-21 2004-07-30 Schering Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de la hepatitis c.
IL137820A (en) * 2000-08-10 2009-06-15 S I S Shulov Inst For Science Pharmaceutical composition for topical administration comprising an analgesic peptide
EP2206496B1 (en) * 2003-05-05 2014-09-17 Probiodrug AG Screening of inhibitors of formation of pyroglutamic acid in amyloid beta peptide
US8338120B2 (en) * 2003-05-05 2012-12-25 Probiodrug Ag Method of treating inflammation with glutaminyl cyclase inhibitors
US20070122507A1 (en) * 2005-05-26 2007-05-31 Palu Afa K Histone deacetylase and tumor necrosis factor converting enzyme inhibition
JP5188731B2 (ja) * 2007-03-02 2013-04-24 雪印メグミルク株式会社 ペプチド

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5419966A (en) * 1977-07-13 1979-02-15 Showa Denko Kk Production of pyroglutamine peptide
WO2002072131A1 (fr) 2001-03-12 2002-09-19 Ajinomoto Co., Inc. Médicaments contre des affections hépatiques
JP2007077594A (ja) 2005-09-12 2007-03-29 Clion Co Ltd アンカー金具埋設軽量気泡コンクリートパネル及びその製造方法並びにその製造装置

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
FUJIWARA K. ET AL.: "The Substrate specificity of pyrrolidone carboxylyl peptidase from Bacillus amyloliquefaciens", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 570, 1979, pages 140 - 148, XP023510694 *
KASAI T. ET AL.: "Transformation of Glutamyl Dipeptides by Heating in Aqueous Solution", AGRIC. BIOL. CHEM., vol. 47, no. 11, 1983, pages 2647 - 2649, XP008119026 *
KOVACS G.L. ET AL.: "Dipeptides delay the onset of morphine withdrawal in the mouse", ACTA PHYSIOLOGICA HUNGARICA, vol. 63, no. 1, 1984, pages 83 - 84, XP008119125 *
See also references of EP2151451A4
SHIBA T. ET AL.: "Synthesis of L-Pyroglutamyl-L-glutaminyl-L-glutamine", BULLETIN OF THE CHEMICAL SOCIETY OF JAPAN, vol. 31, 1958, pages 244 - 245, XP008119048 *
ULIANA J.A. ET AL.: "Pyrrolidonecarboxylyl peptidase: Studies on the specificity of the enzyme", ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol. 131, 1969, pages 561 - 565, XP024803959 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012029616A (ja) * 2010-07-30 2012-02-16 Ogawa & Co Ltd 風味増強剤
JP2018518192A (ja) * 2015-05-04 2018-07-12 浙江海正薬業股▲ふん▼有限公司Ｚｈｅｊｉａｎｇ Ｈｉｓｕｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ ＣＯ．，ＬＴＤ． ブロッコリータンパク質のペプチドを調製する方法、それによって調製されたブロッコリータンパク質のペプチド、および、その使用

Also Published As

Publication number Publication date
KR20090129489A (ko) 2009-12-16
KR101566036B1 (ko) 2015-11-04
US20100190723A1 (en) 2010-07-29
CN101687909B (zh) 2013-12-18
AU2008230460A1 (en) 2008-10-02
CA2681593A1 (en) 2008-10-02
EP2151451A4 (en) 2010-06-02
CN101687909A (zh) 2010-03-31
EP2151451A1 (en) 2010-02-10
JPWO2008117730A1 (ja) 2010-07-15

Similar Documents

Publication Publication Date Title
WO2011118976A3 (en) Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same
WO2007112000A3 (en) Treatment of pain
WO2005023866A3 (en) Peptides that inhibit complement activation
WO2008117730A1 (ja) 肝疾患の予防または治療用組成物
EP1626055A3 (en) Non-mammalian GnRH analogs and uses thereof in the regulation of the immune system
BRPI0512213A (pt) método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
BRPI0406883A (pt) Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
HK1198869A1 (en) Combination treatments for hepatitis c
TW200639159A (en) Treatment of pain
ATE496048T1 (de) Phenylcarboxamidverbindungen zur schmerzbehandlung
WO2009025785A3 (en) Cb2 receptor ligands for the treatment of pain
RU2010136914A (ru) Средство и продукт питания для профилактики/уменьшения проявлений функционального расстройства пищеварения
WO2008062446A3 (en) An extended release composition of levetiracetam, which exhibits no adverse food effect
WO2007092469A3 (en) Combination of organic compounds
WO2007014943A3 (en) Therapy for neurological diseases
CA2583764A1 (en) Thrombopoietin activity modulating compounds and methods
WO2006121995A3 (en) Methods for treating nephrolithiasis
WO2008016640A3 (en) Use of poloxamer for the prevention and/or treatment of heart failure
WO2007014253A3 (en) Method of treating or preventing tissue deterioration, injury or damage due to congestive heart failure
WO2007110709A3 (en) Formulations of tipifarnib for intravenous administration
WO2007000770A3 (en) Protein kinase c inhibitors for prevention of insulin resistance and type 2 diabetes
WO2005115432A3 (en) Treatment of ocular diseases and disorders using lantibiotic compositions
WO2005004854A3 (fr) Utilisation de la betaine pour le traitement des arterites
TW200616644A (en) Medicine for prevention or treatment of diabetes

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880015214.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08722517

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009506311

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2681593

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008230460

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008722517

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008230460

Country of ref document: AU

Date of ref document: 20080319

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20097022163

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12532765

Country of ref document: US